Analysed CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) News Sources
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
07-05-2026
yahoo.com
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)
10-05-2026
yahoo.com
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
14-05-2026
yahoo.com
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
17-05-2026
fool.com
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
20-05-2026
yahoo.com
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million
24-05-2026
fool.com
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
09-06-2026
yahoo.com
What is the current price of CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ)?
The current price of CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) is $14.9.
CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) absolute price change since previous trading day?
The absolute price change of CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) since the previous trading day is $0.63.
CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) percentage price change since previous trading day?
The percentage price change of CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) since the previous trading day is 4.4149%.
What is the most recent average sentiment score for CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ)?
The most recent average sentiment score for CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ)?
The most recent sentiment for CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ) is .
SEC-8K** Filing Available For CORVUS PHARMACEUTICALS INC (CRVS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.